Comment on: Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis

J Antimicrob Chemother. 2020 Dec 1;75(12):3696-3697. doi: 10.1093/jac/dkaa348.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aminoglycosides* / adverse effects
  • Anti-Bacterial Agents / adverse effects
  • Humans
  • Protein Synthesis Inhibitors
  • Pyelonephritis* / drug therapy

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Protein Synthesis Inhibitors